Influenza

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

NCT00479648 | PHASE 2 | INTERVENTIONAL

Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.

1 Sites

612 Participants

Recruiting

18 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Chiltern International

Slough,United Kingdom

Study Eligibility Criteria

Inclusion Criteria

* Aged ≥ 18 to ≤ 45 OR ≥ 60
* Ability to provide pre-vaccination venous blood sample

Exclusion Criteria

* History of clinically significant medical conditions
* Immunomodulative therapy
* Acute infection

Additional Studies

Additional studies can be found at ClinicalTrials.gov